Literature DB >> 16406977

Saturation technique does not improve cancer detection as an initial prostate biopsy strategy.

J Stephen Jones1, Amit Patel, Lynn Schoenfield, John C Rabets, Craig D Zippe, Cristina Magi-Galluzzi.   

Abstract

PURPOSE: We reported on the results of a sequential cohort study comparing office based saturation prostate biopsy to traditional 10-core sampling as an initial biopsy.
MATERIALS AND METHODS: Based on improved cancer detection of office based saturation prostate biopsy repeat biopsy, we adopted the technique as an initial biopsy strategy to improve cancer detection. Two surgeons performed 24-core saturation prostate biopsies in 139 patients undergoing initial biopsy under periprostatic local anesthesia. Indication for biopsy was an increased PSA of 2.5 ng/dl or greater in all patients. Results were compared to those of 87 patients who had previously undergone 10-core initial biopsies.
RESULTS: Cancer was detected in 62 of 139 patients (44.6%) who underwent saturation biopsy and in 45 of 87 patients (51.7%) who underwent 10-core biopsy (p >0.9). Breakdown by PSA level failed to show benefit to the saturation technique for any degree PSA increase. Men with PSA 2.5 to 9.9 ng/dl were found to have cancer in 53 of 122 (43.4%) saturation biopsies and 26 of 58 (44.8%) 10-core biopsies. Complications included 3 cases of prostatitis in each group. Rectal bleeding was troublesome enough to require evaluation only in 3 men in the saturation group and 1 in the 10-core group.
CONCLUSIONS: Although saturation prostate biopsy improves cancer detection in men with suspicion of cancer following a negative biopsy, it does not appear to offer benefit as an initial biopsy technique. These findings suggest that further efforts at extended biopsy strategies beyond 10 to 12 cores are not appropriate as an initial biopsy strategy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16406977     DOI: 10.1016/S0022-5347(05)00211-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  48 in total

Review 1.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

2.  Is repeat biopsy for isolated high-grade prostatic intraepithelial neoplasia necessary?

Authors:  Arnold I Chin; Dhiren S Dave; Jacob Rajfer
Journal:  Rev Urol       Date:  2007

3.  Prostate biopsy: current status and limitations.

Authors:  Joseph C Presti
Journal:  Rev Urol       Date:  2007

Review 4.  Strategies for repeat prostate biopsies.

Authors:  Martha K Terris
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

5.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

6.  Transperineal template prostate biopsies in men with raised PSA despite two previous sets of negative TRUS-guided prostate biopsies.

Authors:  Shady Nafie; Raj P Pal; John P Dormer; Masood A Khan
Journal:  World J Urol       Date:  2013-12-14       Impact factor: 4.226

Review 7.  Standards for prostate biopsy.

Authors:  Marc A Bjurlin; Samir S Taneja
Journal:  Curr Opin Urol       Date:  2014-03       Impact factor: 2.309

Review 8.  Prostate biopsy for the interventional radiologist.

Authors:  Cheng William Hong; Hayet Amalou; Sheng Xu; Baris Turkbey; Pingkun Yan; Jochen Kruecker; Peter A Pinto; Peter L Choyke; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2014-02-26       Impact factor: 3.464

Review 9.  Saturation biopsies for prostate cancer: current uses and future prospects.

Authors:  Nicolas B Delongchamps; Gabriel P Haas
Journal:  Nat Rev Urol       Date:  2009-11-10       Impact factor: 14.432

10.  Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting.

Authors:  A V Taira; G S Merrick; R W Galbreath; H Andreini; W Taubenslag; R Curtis; W M Butler; E Adamovich; K E Wallner
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-09-29       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.